HRP20120918T1 - Aminopirazolski spoj - Google Patents

Aminopirazolski spoj Download PDF

Info

Publication number
HRP20120918T1
HRP20120918T1 HRP20120918AT HRP20120918T HRP20120918T1 HR P20120918 T1 HRP20120918 T1 HR P20120918T1 HR P20120918A T HRP20120918A T HR P20120918AT HR P20120918 T HRP20120918 T HR P20120918T HR P20120918 T1 HRP20120918 T1 HR P20120918T1
Authority
HR
Croatia
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
compound according
intended
Prior art date
Application number
HRP20120918AT
Other languages
English (en)
Croatian (hr)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120918(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120918T1 publication Critical patent/HRP20120918T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20120918AT 2008-12-16 2009-12-08 Aminopirazolski spoj HRP20120918T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
HRP20120918T1 true HRP20120918T1 (hr) 2012-12-31

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120918AT HRP20120918T1 (hr) 2008-12-16 2009-12-08 Aminopirazolski spoj

Country Status (38)

Country Link
US (2) US20100286139A1 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
BR112013022697A2 (pt) * 2011-03-07 2019-09-24 Fond Telethon inibidores de fosforilação de tfeb e usos dos mesmos
WO2012172069A1 (en) * 2011-06-15 2012-12-20 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
ES2900184T3 (es) 2014-08-11 2022-03-16 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
ES2849974T3 (es) * 2016-11-17 2021-08-24 Bristol Myers Squibb Co Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345926B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
RU2325387C2 (ru) 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
EP1899329B1 (en) * 2005-07-01 2011-10-05 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1940847A2 (en) * 2005-10-06 2008-07-09 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
JP5144532B2 (ja) 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
JP2010527999A (ja) 2007-05-23 2010-08-19 フアーマコペイア・エル・エル・シー ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
CO6331442A2 (es) 2011-10-20
PT2379557E (pt) 2013-01-14
AR074240A1 (es) 2011-01-05
JP2012512158A (ja) 2012-05-31
HN2011001697A (es) 2013-11-26
CN102232075B (zh) 2013-12-11
AU2009330503A1 (en) 2010-07-01
CY1113637T1 (el) 2016-06-22
TN2011000292A1 (en) 2012-12-17
PE20110549A1 (es) 2011-08-04
US7897600B2 (en) 2011-03-01
CA2744714A1 (en) 2010-07-01
NZ592641A (en) 2013-01-25
MX2011006441A (es) 2011-07-19
TWI440640B (zh) 2014-06-11
EP2379557A1 (en) 2011-10-26
JO2833B1 (en) 2014-09-15
EA019554B1 (ru) 2014-04-30
ZA201103942B (en) 2012-08-29
SG172202A1 (en) 2011-07-28
TW201024301A (en) 2010-07-01
PA8851101A1 (es) 2010-07-27
IL213065A0 (en) 2011-07-31
BRPI0923048A2 (pt) 2018-09-25
DK2379557T3 (da) 2012-12-17
KR101300458B1 (ko) 2013-08-30
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
UA104743C2 (ru) 2014-03-11
US20100286139A1 (en) 2010-11-11
CR20110341A (es) 2011-07-13
JP5509217B2 (ja) 2014-06-04
EP2379557B1 (en) 2012-10-31
ES2396617T3 (es) 2013-02-22
EA201170831A1 (ru) 2011-12-30
ECSP11011132A (es) 2011-07-29
US20100152181A1 (en) 2010-06-17
KR20110084993A (ko) 2011-07-26
CN102232075A (zh) 2011-11-02
DOP2011000190A (es) 2011-07-31
WO2010074947A1 (en) 2010-07-01
PL2379557T3 (pl) 2013-03-29
SI2379557T1 (sl) 2013-02-28
CA2744714C (en) 2013-06-25
HK1160109A1 (en) 2012-08-10
AU2009330503B2 (en) 2012-06-07
CL2011001445A1 (es) 2011-11-11
MY158691A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
HRP20120918T1 (hr) Aminopirazolski spoj
JP2012512158A5 (enExample)
IL291489A (en) Preparation of (s)-4-(8-amino-3-(1-but-2-inoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
FI3805222T3 (fi) 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa
UA115320C2 (uk) Інгібітори кінази
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX387669B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
PH12013501221A1 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
MY164705A (en) Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor
NZ703152A (en) Dosing regimen for janus kinase (jak) inhibitors
WO2014093583A3 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
PH12014501278A1 (en) Kinase inhibitors
TW200730531A (en) 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amine
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof